A5013739445- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Teaching and Learning Programming
- Open Education and E-Learning
- CNS Lymphoma Diagnosis and Treatment
- COVID-19 and healthcare impacts
- Cancer Treatment and Pharmacology
- Integrated Circuits and Semiconductor Failure Analysis
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Cutaneous lymphoproliferative disorders research
- Glioma Diagnosis and Treatment
- Mobile Learning in Education
- Economic and Financial Impacts of Cancer
- Brain Metastases and Treatment
- Architecture and Computational Design
- Manufacturing Process and Optimization
- Chronic Myeloid Leukemia Treatments
- Augmented Reality Applications
- COVID-19 Clinical Research Studies
- Hematopoietic Stem Cell Transplantation
- Immunotherapy and Immune Responses
- Cytomegalovirus and herpesvirus research
- Virus-based gene therapy research
Johnson & Johnson (United States)
2024
Atlantic Technological University
2023
Janssen (United States)
2023
Technological University Dublin
2023
Oregon Health & Science University
2018-2022
Oregon Health and Science University Hospital
2019
Abramson Cancer Center
2016-2017
University of Pennsylvania
2009-2017
UPMC Hillman Cancer Center
2012-2017
Hospital of the University of Pennsylvania
2017
Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)–directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or refractory multiple myeloma. We investigated cilta-cel earlier treatment lines lenalidomide-refractory disease. Download PDF of the Research Summary. In this phase 3, randomized, open-label trial, we assigned myeloma to receive physician's choice standard care. All had received one three previous treatment. The primary outcome was...
Salvage chemotherapy followed by autologous stem cell transplant (ASCT) remains the current standard of care for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) chemosensitive disease. The addition rituximab results in improved overall survival (OS) after first-line treatment, but cure rates salvage therapy ASCT are inferior when compared to historical controls. Historically, DLBCL disease progression following have had an extremely poor prognosis a median OS 3...
Objective. A prospective observational study of mycophenolate mofetil (MMF) treatment in patients with diffuse progressive cutaneous systemic sclerosis (SSc) recent onset. Methods. Twenty-five previously untreated consecutive recent-onset (< 24 mo) SSc received MMF as the only disease-modifying therapy. Modified Rodnan skin score (mRSS) and affected body surface area (BSA) were compared from initiation to end. Pulmonary function tests performed at same institution before therapy end...
Abstract Chimeric antigen receptor T‐cell therapy (CAR T) is a novel intervention for relapsed/refractory diffuse large B‐cell lymphoma (R/R DLBCL) and other hematologic malignancies. However, it associated with prolonged toxicity (PHT) that unpredictable can significantly impair patients' quality of life. Reported here single‐center experience PHT in adult patients R/R DLBCL who received commercial CAR between March 1, 2018 May 30, 2020. Prolonged was defined as ≥ grade 3 neutropenia or...
Chimeric antigen receptor T cell (CAR-T) therapy is approved for treatment of relapsed/refractory (R/R) diffuse large B lymphoma (DLBCL). Here we evaluate whether comorbidities, calculated using the Cumulative Illness Rating Scale (CIRS), predict survival these patients. A retrospective chart review was performed at 4 academic institutions. All patients who underwent leukapheresis commercial CAR-T R/R DLBCL were included. CIRS scores time leukapheresis. High comorbidity defined as either ≥7...
We conducted a phase I/II multicenter trial using 6 cycles of brentuximab vedotin (BV) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for treatment patients CD30-positive (+) B-cell lymphomas. Thirty-one were evaluable toxicity 29 efficacy including 22 primary mediastinal lymphoma (PMBCL), 5 diffuse large (DLBCL), 2 gray zone (GZL). There no treatment-related deaths; 32% had non-hematological grade 3/4 toxicities. The overall response rate was 100% (95%...
7506 Background: Despite recent advances in the treatment (tx) of transplant ineligible/not intended NDMM, most pts still relapse and require alternative txs, highlighting a need for new frontline tx options with mechanisms action to improve pt outcomes. Teclistamab (tec) demonstrated rapid, deep, durable responses MajesTEC-1 trial (NCT03145181/NCT04557098). Preliminary data from MajesTEC-2 (NCT04722146) that tec, daratumumab (dara), lenalidomide (len) combination (tec + DR) is tolerable,...
Patients with relapsed/refractory Hodgkin lymphoma (RR-HL) who progress or relapse following autologous stem cell transplantation (ASCT) have historically had a poor prognosis. Several novel agents, particularly brentuximab vedotin, shown efficacy in this setting. However, there remains paucity of data characterizing outcomes outside clinical trials and how these agents impacted prognosis general population patients RR-HL. Here, we conducted retrospective analysis to evaluate 87 RR-HL...
Primary mediastinal B-cell lymphoma (PMBL) is a subtype of diffuse large (DLBCL) that arises in the mediastinum from B-cells thymic origin. Optimal management patients with PMBL remains controversial. The present study evaluates outcomes 27 treated R-CHOP or without radiation therapy (RT). It investigates role both interim and posttreatment fluorodeoxyglucose-positron emission tomography (FDG-PET) as prognostic markers outcome. Additionally, it assesses postprogression therapies six who had...
Aim: To describe the long-term outcomes of patients with lymphoma in CNS treated rituximab, temozolomide and high-dose methotrexate without consolidation therapy. Patients & methods: A retrospective cohort study 46 consecutive primary (PCNSL, 27 patients) or secondary involvement diffuse large B-cell (DLBCL, 19 who were rituximab on day 1 combination (days 15) 1–5) 28-day cycles further consolidation. Results: Median follow-up was 21.2 months. received a median five (range 1–15). overall...
120 Background: Brentuximab vedotin (BV) is an immunoconjugate used in Hodgkin lymphoma (HL) and other CD30+ lymphomas. The dose-limiting adverse effect peripheral neuropathy (BIPN). Predictors of BIPN, on outcomes, the biopsychosocial impact are not well defined. Methods: We conducted a single institution, mixed-methods study patients (pts) who received BV between 1/2010 5/2016. A retrospective analysis was all pts; open-ended survey given to pts seen prior year. univariate examined...
7532 Background: CD19-targeted chimeric antigen receptor-engineered (CD19 CAR) T cells achieve high response rates in patients (pts) with relapsed or refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (NHL), but are limited by cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS). Pivotal trial data suggested distinct toxicity risks across CD19 CAR T-cell products, differences pt disease characteristics may have confounded these observations. Thus, we...